Abstract
FK482 is an oral aminothiazolyl hydroxyimino cephalosporin with a C-3 vinyl group. Its activity was compared with those of cephalexin, cefuroxime, cefixime, and amoxicillin-clavulanate. FK482 inhibited 90% of Staphylococcus aureus isolates at 1 micrograms/ml and 90% of Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus pneumoniae isolates at less than or equal to 0.012 micrograms/ml, superior to cephalexin and cefuroxime and similar to cefixime. It did not inhibit oxacillin-resistant S. aureus. FK482 inhibited 90% of Enterococcus faecalis isolates at 8 micrograms/ml. Although 90% of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella species, and Shigella species isolates were inhibited by less than or equal to 2 micrograms/ml, FK482 was less active than cefixime against Citrobacter, Enterobacter, Morganella, Serratia, and Providencia species, with MICs for many isolates of greater than 8 micrograms/ml. FK482 inhibited Haemophilus influenzae and Neisseria gonorrhoeae at concentrations comparable to that of cefixime and superior to those of cephalexin and cfaclor. Bacteroides and Pseudomonas species were resistant. FK482 was not hydrolyzed by the TEM-1 and TEM-2 beta-lactamases but was hydrolyzed by TEM-3 and the Proteus vulgaris enzyme. It had a high affinity for chromosomal beta-lactamases.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chin N. X., Neu H. C. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746. Antimicrob Agents Chemother. 1988 May;32(5):671–677. doi: 10.1128/aac.32.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fass R. J., Helsel V. L. In vitro activity of U-76,252 (CS-807), a new oral cephalosporin. Antimicrob Agents Chemother. 1988 Jul;32(7):1082–1085. doi: 10.1128/aac.32.7.1082. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Barry A. L. Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines. Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):802–807. doi: 10.1007/BF01975055. [DOI] [PubMed] [Google Scholar]
- Knapp C. C., Sierra-Madero J., Washington J. A. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone. Antimicrob Agents Chemother. 1988 Dec;32(12):1896–1898. doi: 10.1128/aac.32.12.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McLinn S. E. Randomized, open label, multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. Pediatr Infect Dis J. 1987 Oct;6(10):997–1001. doi: 10.1097/00006454-198710000-00042. [DOI] [PubMed] [Google Scholar]
- Neu H. C., Chin N. X., Labthavikul P. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother. 1984 Aug;26(2):174–180. doi: 10.1128/aac.26.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Chin N. X., Labthavikul P. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). Antimicrob Agents Chemother. 1986 Sep;30(3):423–428. doi: 10.1128/aac.30.3.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]